The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.

EP: 1.Overview of RSV Patient Populations

EP: 2.Complications Associated with RSV Infections

Now Viewing

EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

EP: 4.RSV: Risk Factors and How It’s Spread

EP: 5.Diagnostic Practices for RSV

EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients

EP: 7.Shared Decision-Making Practices in RSV

EP: 8.Financial and Clinical Benefits of RSV Immunization

EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

EP: 10.Addressing Vaccine Fatigue

EP: 11.Identifying Patients Eligible for RSV Vaccine

EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines

EP: 13.Improving Insurance Coverage for RSV Vaccines

EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation

EP: 15.Key Takeaways on RSV Vaccination

Video content above is prompted by the following questions:

• Please describe the economic burden of RSV, especially in adults aged 50-59 and those 60 and older.
• What are the main drivers of healthcare resource utilization in high-risk patients with RSV?
  

Related Videos

Related Content

Advertisement

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

Pearl Steinzor

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

November 14th 2024

Impact of RSV on Hospitalizations in US Adults Prior to Vaccine Introduction

Pearl Steinzor

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.

October 23rd 2024

GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults

Sophia Abene

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

October 21st 2024

Clinical Outcomes, Mortality Risk Factor of RSV, Influenza in Hospitalized Adults

Pearl Steinzor

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe.

October 9th 2024

Identifying Postdischarge Care Needs Among Adults Hospitalized With RSV

Pearl Steinzor

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.

Related Content

Advertisement

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

Pearl Steinzor

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

November 14th 2024

Impact of RSV on Hospitalizations in US Adults Prior to Vaccine Introduction

Pearl Steinzor

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.

October 23rd 2024

GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults

Sophia Abene

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

October 21st 2024

Clinical Outcomes, Mortality Risk Factor of RSV, Influenza in Hospitalized Adults

Pearl Steinzor

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe.

October 9th 2024

Identifying Postdischarge Care Needs Among Adults Hospitalized With RSV

Pearl Steinzor

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.